Generation Bio Co. (NASDAQ:GBIO) COO Antoinette Paone Sells 6,719 Shares

Generation Bio Co. (NASDAQ:GBIO) COO Antoinette Paone sold 6,719 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $2.74, for a total value of $18,410.06. Following the completion of the sale, the chief operating officer now directly owns 13,807 shares in the company, valued at approximately $37,831.18. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Generation Bio Stock Up 4.3 %

Shares of NASDAQ:GBIO opened at $2.44 on Thursday. The company has a market cap of $162.33 million, a P/E ratio of -0.96 and a beta of 2.83. The business has a fifty day simple moving average of $3.06 and a 200-day simple moving average of $2.72. Generation Bio Co. has a 52 week low of $0.86 and a 52 week high of $6.98.

Generation Bio (NASDAQ:GBIO) last released its quarterly earnings results on Monday, May 13th. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.76). Generation Bio had a negative return on equity of 82.33% and a negative net margin of 1,696.87%. The company had revenue of $4.06 million during the quarter, compared to analysts’ expectations of $3.02 million. Sell-side analysts expect that Generation Bio Co. will post -1.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Generation Bio

A number of large investors have recently bought and sold shares of GBIO. PFG Advisors acquired a new stake in shares of Generation Bio in the first quarter valued at approximately $41,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Generation Bio in the first quarter valued at approximately $74,000. Panagora Asset Management Inc. bought a new stake in Generation Bio during the fourth quarter worth approximately $49,000. Kestra Private Wealth Services LLC acquired a new position in shares of Generation Bio during the 4th quarter valued at $50,000. Finally, SG Americas Securities LLC boosted its stake in Generation Bio by 260.9% during the fourth quarter. SG Americas Securities LLC now owns 48,470 shares of the company’s stock valued at $80,000 after buying an additional 35,040 shares in the last quarter. Institutional investors own 95.22% of the company’s stock.

Analysts Set New Price Targets

GBIO has been the subject of a number of recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price target on shares of Generation Bio in a report on Tuesday, May 14th. Wedbush restated an “outperform” rating and set a $5.00 target price on shares of Generation Bio in a research report on Tuesday, May 14th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $8.00.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.